HC Wainwright & Co. Maintains Neutral on Fate Therapeutics, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Neutral rating on Fate Therapeutics (NASDAQ:FATE) but lowered the price target from $7 to $5.
May 16, 2024 | 11:39 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HC Wainwright & Co. has maintained a Neutral rating on Fate Therapeutics but lowered the price target from $7 to $5, indicating a cautious outlook.
The lowered price target from $7 to $5 suggests a less optimistic view on the stock's potential, which could lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100